| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7524834 | ASTRAZENECA | Sterile powders, formulations, and methods for producing the same |
Nov, 2018
(5 years ago) | |
| US6598603 | ASTRAZENECA | Method for treating respiratory diseases |
Dec, 2018
(5 years ago) | |
| US6899099 | ASTRAZENECA | Method for treating a respiratory disease |
Dec, 2018
(5 years ago) | |
|
US7524834 (Pediatric) | ASTRAZENECA | Sterile powders, formulations, and methods for producing the same |
May, 2019
(4 years ago) | |
|
US6598603 (Pediatric) | ASTRAZENECA | Method for treating respiratory diseases |
Jun, 2019
(4 years ago) | |
|
US6899099 (Pediatric) | ASTRAZENECA | Method for treating a respiratory disease |
Jun, 2019
(4 years ago) | |
Pulmicort Respules is owned by Astrazeneca.
Pulmicort Respules contains Budesonide.
Pulmicort Respules has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Pulmicort Respules are:
- US7524834
- US6598603
- US6899099
- US7524834*PED
- US6598603*PED
- US6899099*PED
Pulmicort Respules was authorised for market use on 08 August, 2000.
Pulmicort Respules is available in suspension;inhalation dosage forms.
Pulmicort Respules can be used as treatment of asthma (maintenance and prophylactic therapy), once daily treatment of asthma with nebulized budesonide.
The generics of Pulmicort Respules are possible to be released after 23 June, 2019.
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 08 August, 2000
Treatment: Treatment of asthma (maintenance and prophylactic therapy); Once daily treatment of asthma with nebulized budesonide
Dosage: SUSPENSION;INHALATION
PULMICORT RESPULES family patents
